nVerses Capital’s Fulgent Genetics FLGT Stock Holding History

nVerses Capital’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,400	Closed	-$52.2K	–	310
2024 Q3	$52.2K	Buy	2,400 +200	+9%	+$4.47K	0.02%	624
2024 Q2	$43.2K	Buy	+2,200	New	+$45.9K	0.03%	624

Other funds holding FLGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

nVerses Capital's FLGT Position: Q4 2024 in Review

nVerses Capital sold out of Fulgent Genetics (FLGT) in Q4 2024, closing a stake of 2,400 shares — an estimated $52.2K sold.

nVerses Capital first reported a position in FLGT in Q2 2024 and held it in 2 quarters. The position peaked at $52.2K in Q3 2024. 189 funds tracked by Wall St. Rank hold FLGT as of Q4 2024.

nVerses Capital reported no remaining Fulgent Genetics position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 2,400 Fulgent Genetics shares in Q4 2024, an estimated $52.2K.
nVerses Capital first reported a position in Fulgent Genetics in Q2 2024 and held it in 2 quarters.
nVerses Capital's Fulgent Genetics position peaked at $52.2K in Q3 2024.
189 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.